Datopotamab Deruxtecan is a new drug which is known in shorter version as Dato Dxd.

Dato Dxd is very promising in breast cancer and Lung cancers that have failed to respond to prior treatments

Dato Dxd belongs a existing new group of cancer drugs known ADCs ( Antibody drug Conjugate).

ADCs involve a combination of carrier molecule and a payload. ADCs go and stick to surface of cancer cells and off load the chemotherapy drug which in turn damages the cancer cell.

Data presented at the an European Cancer congress in Madrid demonstrates high degree of cancer activity. Hopefully the drug will be available for clinical use very shortly after it has been properly licensed by regulatory authorities.

References

Datopotamab deruxtecan met the PFS endpoint in previously treated NSCLC

Antibody–drug conjugates improve outcomes for patients with inoperable or metastatic breast cancer

Disclaimer: Please note – This blog is NOT medical advice. This blog is NOT a expert medical opinion on various topics. This blog is purely for information only and do check the sources where cited. Please DO consult your own doctor to discuss concerns and options relevant to you. The views expressed in this blog are NOT, in any way whatsoever, intended to be a substitute for professional advice. The blog is NOT previewed, commissioned or otherwise endorsed, in any way, by any organisation that the author is associated with. The views expressed in this blog likely represents some of the author’s personal views held at the time of drafting the blog and MAY CHANGE overtime, particularly when new evidence comes to light.